Table 1.
Patient characteristic.
| Control (n = 20) | Post AC (n = 44) |
P value by ANOVA | ||
|---|---|---|---|---|
| CTRCD (−) (n = 37) | CTRCD (+) (n = 7) | |||
| Age at cancer diagnosis, years old | 61.6 ± 11.2 | 52.9 ± 10.6** | 50.9 ± 11.4* | 0.02 |
| Dox-converted dose, mg/m2 | – | 254.8 ± 35.9 | 302.3 ± 35.0 | – |
| -Doxorubicin, n (%) | – | 4 (11) | 6 (86)‡ | – |
| -Epirubicin, n (%) | – | 33 (89) | 0 (0)‡ | – |
| -Dox plus epirubicin, n (%) | – | 0 (0) | 1 (14)† | – |
| Elapsed time from AC treatment, Months | – | 80.8 ± 47.1 | 52.6 ± 30.8 | – |
| BMI§, kg/m2 | 23.2 ± 4.6 | 23.3 ± 3.6 | 22.7 ± 1.9 | 0.92 |
| BSA§, m2 | 1.5 ± 0.1 | 1.6 ± 0.1 | 1.5 ± 0.1 | 0.77 |
| Hypertension, n (%) | 6 (30) | 12 (32) | 4 (57) | 0.40 |
| Dyslipidemia, n (%) | 11 (55) | 1 (3)** | 1 (14) | <0.01 |
| Diabetes mellitus, n (%) | 2 (10) | 12 (32) | 1 (14) | 0.13 |
| eGFR§, mL/min/1.73 m2 | 73.6 ± 14.3 | 85.2 ± 18.1* | 90.6 ± 13.2* | 0.02 |
| BNP§, pg/mL | 15.6 ± 8.5 | 22.5 ± 19.8 | 22.7 ± 18.9 | 0.32 |
| Hs-cTnT§, ng/mL | 0.006 ± 0.003 | 0.005 ± 0.003 | 0.005 ± 0.003 | 0.87 |
| LVEF by UCG§, % | 66.6 ± 3.2 | 63.2 ± 3.3* | 38.9 ± 14.9**‡ | <0.01 |
| EDV by UCG§, mL | 60.0 ± 15.3 | 64.5 ± 14.6 | 102.5 ± 31.7**‡ | <0.01 |
| ESV by UCG§, mL | 20.1 ± 5.3 | 23.7 ± 5.8 | 66.6 ± 35.6**‡ | <0.01 |
| GLS by UCG§, % | −18.7 ± 2.4 | −17.5 ± 2.8 | −10.7 ± 5.5**‡ | <0.01 |
| ECV by CCT§, %# | 26.2 ± 2.5 | 27.5 ± 3.1 | 30.3 ± 4.8**† | 0.02 |
AC: anthracycline, CTRCD: cancer therapeutics–related cardiac dysfunction, ANOVA: analysis of variance, Dox: doxorubicin, BMI: body mass index, BSA: body surface area, eGFR: estimated glomerular filtration rate, BNP: B-type natriuretic peptide, Hs-cTnT: high-sensitivity cardiac Troponin T, LVEF: left ventricular ejection fraction, UCG: echocardiography, EDV: end-diastolic volume, ESV: end-systolic volume, GLS: global longitudinal strain, ECV: extracellular volume fraction, CCT: cardiac computed tomography.
‡:P < 0.01 vs CTRCD(-), §:at investigation.
#: normal reference value is 23–28%.
*
:P < 0.05 vs control, **:P < 0,01 vs control, †:P < 0.05 vs CTRCD(−).